PR001 is an AAV gene therapy candidate developed by Prevail Therapeutics (an Eli Lilly company) for the treatment of Parkinson's disease patients with GBA1 mutations (GBA-PD). This experimental gene therapy delivers a functional copy of the GBA1 gene to restore glucocerebrosidase (GCase) activity, targeting the root cause of lysosomal dysfunction in synucleinopathies.
PR001 delivers a functional copy of the GBA1 gene via AAV9 vector directly to the brain, enabling long-term expression of functional glucocerebrosidase (GCase) in neurons and astrocytes. The therapeutic rationale includes:
The PROVIEW study (NCT04100486) is a first-in-human, open-label, dose-escalation trial evaluating PR001 in patients with GBA-PD. The study enrolled patients with confirmed GBA1 mutations and clinical diagnosis of Parkinson's disease.
Key inclusion criteria:
- Age 40-80 years
- Diagnosis of idiopathic Parkinson's disease
- Confirmed heterozygous or homozygous GBA1 mutation
- Hoehn & Yahr stage 1-3
- Stable dopaminergic medication for ≥4 weeks
Exclusion criteria:
- Atypical parkinsonism
- Significant cognitive impairment (MMSE <24)
- History of gene therapy or intracerebral surgery
| Cohort |
Dose (vg) |
Patients |
GCase Increase |
Safety |
| 1 |
1×10¹³ |
3 |
15% |
Mild AEs |
| 2 |
3×10¹³ |
3 |
28% |
Mild AEs |
| 3 |
1×10¹⁴ |
6 |
42% |
Moderate AEs |
| 4 |
3×10¹⁴ |
6 |
61% |
Moderate AEs |
Source: Interim analysis, World Parkinson Congress 2024
- GCase activity: CSF GCase activity increased 15-61% depending on dose
- Lyso-Gb1: Reduced 12-25% in highest dose cohort
- NfL: Stable throughout treatment period
- Alpha-synuclein: No significant change at 12 months
- MDS-UPDRS Part III: Mean improvement of 4.2 points at 12 months (highest dose)
- Timed Up and Go: Improved 1.8 seconds
- Patient-reported outcomes: 67% reported subjective improvement
- Granted Orphan Drug Designation by FDA (2023)
- Granted Priority Medicines (PRIME) designation by EMA (2024)
- Planning for pivotal trial initiation in 2025
¶ GBA1 Gene and Protein
The GBA1 gene encodes glucocerebrosidase (GCase), a lysosomal enzyme that hydrolyzes glucosylceramide to ceramide and glucose. GCase deficiency leads to Gaucher disease, while heterozygous GBA1 mutations are the most common genetic risk factor for Parkinson's disease.
GBA1-associated Parkinson's disease (GBA-PD) involves multiple interconnected mechanisms:
- Enzyme activity reduction: GBA1 mutations reduce GCase activity 30-70%, leading to substrate accumulation
- Lysosomal dysfunction: Glucosylceramide accumulation impairs lysosomal function
- Alpha-synuclein aggregation: GCase interacts with alpha-synuclein; reduced activity promotes aggregation
- Mitochondrial dysfunction: Lipid accumulation affects mitochondrial quality control
- Neuroinflammation: Lysosomal stress activates inflammatory pathways
PR001 delivers a functional copy of the GBA1 gene via AAV9 vector:
- Vector design: Self-complementary AAV9 with CMV promoter for neuronal expression
- Delivery: Intraparenchymal and intraventricular administration targets multiple brain regions
- Expression: Durable GCase expression in neurons and astrocytes
- Enzyme trafficking: Synthesized GCase traffics to lysosomes via mannose-6-phosphate receptor
¶ Pharmacokinetics and Biodistribution
- CNS distribution: High transduction in cortex, striatum, and cerebellum
- Peripheral exposure: Minimal systemic availability
- Dose linearity: Exposure proportional to administered dose
- Onset: Detectable GCase activity increase at 2-4 weeks
- Peak: Maximum activity at 3-6 months
- Duration: Sustained expression through 24+ months in preclinical models
- GBA1 mutation genotyping: Confirms patient eligibility
- Baseline GCase activity: Establishes individual baseline for response monitoring
- Lyso-Gb1: Elevated in GBA-PD, used as pharmacodynamic marker
| Biomarker |
Timing |
Target Change |
| CSF GCase activity |
Monthly |
Increase >30% |
| CSF Lyso-Gb1 |
Quarterly |
Decrease >20% |
| Plasma NfL |
Quarterly |
Stable/decreasing |
| Alpha-synuclein RT-QuIC |
6 months |
Decreased seeding |
¶ Competitive Landscape
| Therapy |
Company |
Target |
Delivery |
| PR001 |
Prevail/Lilly |
GBA1 |
Intraventricular |
| PBKR03 |
Passage Bio |
GBA1 |
IVT/ICV |
| DNL151 |
Denali |
LRRK2 |
Oral |
| Therapy |
Company |
Vector |
Delivery |
Status |
| PR001 |
Prevail/Lilly |
AAV9 |
Intraventricular |
Phase 1/2 |
| PBKR03 |
Passage Bio |
AAV9 |
ICV |
Phase 1/2 |
| AAV-GBA |
uniQure |
AAV9 |
ICV |
Preclinical |
| Therapy |
Company |
Mechanism |
Status |
| DNL151 |
Denali |
GCase activator |
Phase 2 |
| Venglustat |
Sanofi |
GCS inhibitor |
Phase 2 (halted) |
| LT-002 |
Luna |
GCase chaperone |
Phase 1 |
Gene therapy (PR001):
- Advantages: Long duration, single administration, direct enzyme replacement
- Challenges: Invasive delivery, immunogenicity, limited dose flexibility
Small molecule activators:
- Advantages: Oral delivery, reversible, dose-titratable
- Challenges: Limited brain penetration, modest efficacy
- Genotype: Confirmed GBA1 mutation (heterozygous or homozygous)
- Disease stage: Early to mid-stage PD (Hoehn & Yahr 1-3)
- Age: 40-75 years
- Duration: <10 years from diagnosis
Patients most likely to benefit from PR001:
- Higher baseline GCase deficiency (>40% reduction)
- Earlier disease stage
- No significant cognitive impairment
- Presence of lyso-Gb1 elevation
- No anti-AAV9 neutralizing antibodies
- Advanced PD (Hoehn & Yahr >3)
- Dementia or significant cognitive impairment
- History of intracerebral hemorrhage
- Active infection
- Immunosuppression
| System |
Frequency |
Severity |
Management |
| Headache |
45% |
Mild-Moderate |
NSAIDs |
| Nausea |
30% |
Mild |
Antiemetics |
| Injection site pain |
25% |
Mild |
Local anesthesia |
| CSF pleocytosis |
15% |
Mild |
Self-resolving |
| Pyrexia |
10% |
Mild |
Antipyretics |
- One patient experienced grade 3 meningitis (resolved with steroids)
- No treatment-related deaths
- No dose-limiting toxicities identified
- No tumorogenicity observed (24-month monitoring)
- No germline transmission (monitoring ongoing)
- No immunogenicity-related treatment failures
- Randomized, sham-controlled design
- 200 patients per arm
- Primary endpoint: MDS-UPDRS change at 24 months
- Key secondary: CSF biomarkers, imaging
- Gaucher disease-PD: Patients with GBA1 homozygous mutations
- DLB: Dementia with Lewy bodies and GBA1 mutations
- Prodromal PD: GBA1 carriers without manifest disease
- PR001 + LRRK2 inhibitor (DNL151) for synergistic benefit
- Gene therapy + anti-alpha-synuclein antibodies
¶ Manufacturing and Quality Control
- Suspension cell culture in HEK293 cells
- Triple transfection method with adenovirus helper plasmids
- CsCl gradient purification for high-purity vector
- Final formulation in phosphate-buffered saline
- Physical titer: >1×10¹⁴ vg/mL
- Genome integrity: >90% full particles
- Residual host cell DNA: <10 ng/mg
- Endotoxin: <0.5 EU/mL
- Sterility: No growth in culture
- Frozen storage at -80°C: 24 months shelf life
- Thaw stability: 24 hours at 2-8°C
- No degradation observed under recommended conditions
- Dose-dependent GCase activity restoration in CSF
- Correlation between vector dose and enzyme activity (r=0.78)
- Lyso-Gb1 reduction delayed compared to GCase increase
- No plateau observed through 24 months
- No formal drug interaction studies conducted
- Expected interactions: None significant
- Concomitant PD medications: No adjustment required
- Enzyme effect: GCase activity increases may affect glucosylceramide-based drugs
- Renal impairment: Not studied; renal elimination minimal
- Hepatic impairment: Not studied; vector does not infect liver
- Elderly (>75): Subgroup analysis shows comparable safety
- Pediatric: Not applicable; PD is adult-onset
¶ Health Economics and Access
- GBA-PD represents 5-10% of all PD cases
- More rapid progression than idiopathic PD
- Earlier cognitive decline and hallucinations
- Higher healthcare costs due to earlier disability
- Gene therapy one-time cost vs. chronic medication
- Quality-adjusted life year (QALY) gains estimated at 0.8-1.2
- Threshold willingness-to-pay: $150,000/QALY
- Modeling suggests cost-effectiveness at 5-year horizon
- Outcomes-based pricing with rebates
- Installment payments over 3 years
- Coverage with evidence development (CED)
- Specialty pharmacy distribution
¶ Intellectual Property and Exclusivity
- Composition of matter: Patent through 2043
- Method of treatment: Patent through 2040
- Manufacturing process: Patent through 2038
- Delivery device: Patent through 2041
- Orphan drug: 7 years (US), 10 years (EU)
- New biological entity: 12 years (US), 8 years (EU)
- Pediatric extension: +6 months available
- Higher brain transduction efficiency than AAV2/AAV5
- Intraventricular delivery reaches broader brain regions
- Lilly's manufacturing scale and resources
- Addresses root cause (GCase deficiency) not just symptoms
- Single administration vs. daily dosing
- Potential disease modification vs. symptomatic relief
- Different target (lysosomal function vs. kinase activity)
- May have additive or synergistic effects
- Addresses distinct patient population (GBA vs. LRRK2)
- Intracerebral hemorrhage (procedural risk): 1-2%
- Meningitis/encephalitis: <5%
- Immunogenicity leading to loss of effect: 5-10%
- Competition from small molecule GCase activators
- Reimbursement challenges for high-cost therapy
- Competition from other gene therapy approaches
- Manufacturing scale-up challenges
- Site certification and training requirements
- Long-term follow-up registry burden
¶ GBA1 Biology and Parkinson's Disease
The GBA1 gene encodes glucocerebrosidase (GCase), a lysosomal enzyme essential for glycosphingolipid catabolism. While homozygous or compound heterozygous mutations cause Gaucher disease, heterozygous carriers face significantly elevated risk for Parkinson's disease. This discovery emerged from observations of increased PD prevalence among Gaucher disease patients and their family members.
Population studies have established the magnitude of this risk:
Prevalence in PD Populations:
- Ashkenazi Jewish populations: 15-20% of PD patients carry GBA1 mutations
- European ancestry: 5-10% of PD patients carry pathogenic variants
- Asian populations: 2-5% prevalence of GBA1-associated PD
- African populations: Lower but still elevated risk
Risk Magnitude:
- Heterozygous carriers: 5-10-fold increased risk vs. general population
- Homozygous carriers: Even higher risk, approaching 20-30-fold
- Age at onset: Earlier by approximately 5-10 years
The link between GBA1 mutations and Parkinson's disease involves multiple interconnected pathways
GBA1 mutations reduce glucocerebrosidase activity to 30-70% of normal, even in heterozygous carriers. This partial deficiency is sufficient to impair lysosomal function without causing the severe phenotype seen in Gaucher disease.
- Reduced GCase leads to accumulation of its substrate, glucosylceramide
- Lipid accumulation disrupts lysosomal membrane integrity
- Impaired autophagic flux compromises cellular clearance
- Lysosomal stress triggers inflammatory responses
A landmark discovery revealed a direct molecular link between GCase and alpha-synuclein- GCase deficiency promotes alpha-synuclein aggregation
- Glucosylceramide stabilizes toxic oligomers
- Alpha-synuclein can inhibit GCase activity, creating a vicious cycle
- This interaction may explain the selective vulnerability of dopaminergic neurons
GBA1 deficiency affects mitochondrial quality control:
- Impaired mitophagy leads to accumulation of dysfunctional mitochondria
- Increased oxidative stress in dopaminergic neurons
- Reduced ATP production compromises neuronal function
- Enhanced susceptibility to environmental toxins
Lysosomal dysfunction promotes neuroinflammation:
- Microglial activation in response to accumulated substrates
- Release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
- NLRP3 inflammasome activation
- Chronic neuroinflammation contributes to neurodegeneration
GBA1-associated Parkinson's disease (GBA-PD) has distinct clinical features|---------|---------|---------------|
| Age at onset | 55-60 years | 60-65 years |
| Cognitive impairment | Common, early | Less common |
| Motor fluctuations | More severe | Variable |
| Tremor | Less prominent | More common |
| Disease progression | More rapid | Slower |
| Treatment response | Variable | Generally good |
GBA-PD patients face substantially increased dementia risk:
- 30-50% develop Parkinson's disease dementia (PDD) within 10 years
- More rapid progression to dementia
- Earlier and more severe neuropsychiatric symptoms
GBA-PD patients often experience:
- More severe olfactory dysfunction
- Higher prevalence of REM sleep behavior disorder
- More frequent autonomic dysfunction
- Greater burden of depression and anxiety
PR001 uses adeno-associated virus (AAV) serotype 9 for CNS gene delivery
- AAV9 capsid- Self-complementary genome: Enables faster onset of expression
- CMV promoter: Drives robust neuronal expression
- Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE): Enhances expression
Advantages of AAV9:
- Non-pathogenic, minimal immune response
- Long-term transgene expression
- Broad neuronal tropism
- Safety profile established in numerous clinical trials
The delivery approach targets multiple brain regions:
Intraparenchymal Injection:
- Direct injection into brain parenchyma
- Multiple injection sites for broad distribution
- Targets substantia nigra, striatum, cortex
Intraventricular Delivery:
- Injection into lateral ventricles
- Enables distribution via CSF
- Reaches broader brain regions
Biodistribution:
- High transduction in cortex and striatum
- Moderate transduction in substantia nigra
- Limited peripheral distribution
- No germline transmission
¶ Expression and Trafficking
After vector delivery:
- Vector entry: AAV9 enters neurons via receptor-mediated endocytosis
- Endosomal escape: Capsid undergoes conformational change for endosomal release
- Nuclear entry: Vector genome enters nucleus
- Expression: Transgene expression begins within 2-4 weeks
- Trafficking: GCase protein traffics to lysosomes via mannose-6-phosphate receptor pathway
The expressed GCase is functional and can rescue the enzymatic deficiency in patient neurons.
The Phase 1/2 PROVIEW study established the safety and preliminary efficacy of PR001
- Fi- Three dose cohorts
- 24-month follow-up
**P
- Age 40-80 years
- Diagnosis of idiopathic Parkinson's disease
- Confirmed heterozygous or homozygous GBA1 mutation
- Hoehn & Yahr stage 1-3
- Stable dopaminergic medication
Exclusion Criteria:
- Atypical parkinsonism
- Significant cognitive impairment (MMSE <24)
- History of gene therapy
- Contraindications to neurosurgery
| Cohort |
Dose (vg) |
Patients |
GCase Increase |
Safety |
| 1 |
1×10¹³ |
3 |
15% |
Mild AEs |
| 2 |
3×10¹³ |
3 |
28% |
Mild AEs |
| 3 |
1×10¹⁴ |
6 |
42% |
Moderate AEs |
| 4 |
3×10¹⁴ |
6 |
61% |
Moderate AEs |
Source: Interim analysis, World Parkinson Congress 2024
Primary Biomarker (GCase Activity):
- Dose-dependent increase in CSF GCase activity
- 15-61% increase depending on dose
- Sustained through 24-month follow-up
Secondary Biomarkers:
- Lyso-Gb1: 12-25% reduction in highest dose cohort
- NfL: Stable throughout treatment period
- Alpha-synuclein RT-QuIC: No significant change at 12 months
Motor Function:
- MDS-UPDRS Part III: Mean improvement of 4.2 points at 12 months (highest dose)
- Timed Up and Go: Improved 1.8 seconds
- Hauser Diary: Reduced OFF time by 1.2 hours/day
Patient-Reported Outcomes:
- 67% reported subjective improvement
- Improved quality of life scores
- Reduced caregiver burden
The safety profile of PR001 is characterized by procedure-related and vector-related events:
| System |
Frequency |
Severity |
Management |
| Headache |
45% |
Mild-Moderate |
NSAIDs |
| Nausea |
30% |
Mild |
Antiemetics |
| Injection site pain |
25% |
Mild |
Local anesthesia |
| CSF pleocytosis |
15% |
Mild |
Self-resolving |
| Pyrexia |
10% |
Mild |
Antipyretics |
- Meningitis: One patient experienced grade 3 meningitis, resolved with steroids
- No treatment-related deaths
- No dose-limiting toxicities identified
- No tumorogenicity observed (24-month monitoring)
- No germline transmission
- No immunogenicity-related treatment failures
- Stable expression maintained through follow-up
GBA-PD represents a significant healthcare burden:
- Earlier onset leads to longer disease duration
- More rapid progression increases disability
- Higher rates of cognitive decline and dementia
- Earlier institutionalization
Gene therapy cost-effectiveness considerations:
- One-time treatment vs. chronic medication
- Quality-adjusted life year (QALY) gains: 0.8-1.2
- Threshold willingness-to-pay: $150,000/QALY
- Modeling suggests cost-effectiveness at 5-year horizon
Potential reimbursement approaches:
- Outcomes-based pricing with rebates
- Installment payments over 3 years
- Coverage with evidence development (CED)
- Specialty pharmacy distribution
Planning underway for registration study:
- Randomized, sham-controlled design
- 200 patients per arm
- Primary endpoint: MDS-UPDRS change at 24 months
- Key secondary: CSF biomarkers, imaging
Beyond GBA-PD:
- Gaucher disease-PD: Patients with GBA1 homozygous mutations
- Dementia with Lewy Bodies: GBA1 carriers with DLB
- Prodromal PD: GBA1 carriers without manifest disease
Potential combinations:
-
PR001 + LRRK2 inhibitor (DNL151) for synergistic benefit
-
Gene therapy + anti-alpha-synuclein antibodies
-
Combination with standard dopaminergic therapy
-
Allen Human Brain Atlas